Registry for Participants With Short Bowel Syndrome
About the study
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS).
- Signed informed consent and medical records release by the participant or a legally acceptable representative
- Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment.
EXCLUSION CRITERIA
Exclusion criteria:
- Participants currently participating in a blinded clinical trial or their extension studies.
- Participants who have never been on PN/IV support.
- Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Short Bowel Syndrome
Participants Needed
1806
Est. Completion Date
Jun 30, 2032
Treatment Type
OBSERVATIONAL
Sponsor
Takeda
ClinicalTrials.gov NCT Identifier
NCT01990040
Study Number
TED-R13-002
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?